Wyeth Pharmaceuticals based in Madison, N J has announced plans to phase out Premarin production at its Rouses Point, NY manufacturing facility. The plan will discontinue all operations by 2008. Sales of Premarin stated to plunge last year after a National Institute of Health study linked long-term use of Premarin to an increased risk for stroke.

The International Academy of Compounding Pharmacists issued a press release accusing Wyeth of `manipulating the law and facts in an attempt to restrict patients’ access to customized bioidentical hormone replacement therapy”. Wyeth will be transferring its Premarin operation to a facility in Newbridge, Ireland.